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Abstract
Our preliminary results indicated that fibrin and poly(lactic-
co-glycolic acid) (PLGA) hybrid scaffold promoted early
chondrogenesis of articular cartilage constructs in vitro. The
aim of this study was to evaluate in vivo cartilaginous tissue
formation by chondrocyte-seeded fibrin/PLGA hybrid
scaffolds. PLGA scaffolds were soaked carefully, in
chondrocyte-fibrin suspension, and polymerized by
dropping thrombin-calcium chloride (CaCl2) solution.
PLGA-seeded chondrocytes were used as a control.
Resulting constructs were implanted subcutaneously, at the
dorsum of nude mice, for 4 weeks. Macroscopic
observation, histological evaluation, gene expression and
sulphated-glycosaminoglycan (sGAG) analyses were
performed at each time point of 1, 2 and 4 weeks post-
implantation. Cartilaginous tissue formation in fibrin/PLGA
hybrid construct was confirmed by the presence of lacunae
and cartilage-isolated cells embedded within basophilic
ground substance. Presence of proteoglycan and
glycosaminoglycan (GAG) in fibrin/PLGA hybrid
constructs was confirmed by positive Safranin O and Alcian
Blue staining. Collagen type II exhibited intense
immunopositivity at the pericellular matrices.
Chondrogenic properties were further demonstrated by the
expression of gene encoded cartilage-specific markers,
collagen type II and aggrecan core protein. The sGAG
production in fibrin/PLGA hybrid constructs was higher
than in the PLGA group. In conclusion, fibrin/PLGA hybrid
scaffold promotes cartilaginous tissue formation in vivo and
may serve as a potential cell delivery vehicle and a structural
basis for articular cartilage tissue-engineering.
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Introduction
Autologous chondrocyte implantation (ACI) has emerged
as a successful viable alternative treatment in orthopaedics
for arthroscopic intervention or joint replacement surgery
(Brittberg et al., 1994; Mandelbaum et al., 2007; Peterson
et al., 2003). Recently, further development of original
ACI has led to the invention of in vitro three-dimensional
(3D) cartilage implants that enabled easier surgical
handling and facilitated cartilaginous tissue formation
(Munirah et al., 2005; Munirah et al., 2007; Willers et
al., 2005). This was supported by numerous investigations
of the potential of full-thickness cartilage restoration,
using 3D implants, in various animal models such as rabbit
(Ito et al., 2005; Shao et al., 2006), goat (Niederauer et
al., 2000), dog (Breinan et al., 2001) and sheep (Munirah
et al., 2007). Since most studies reported implantation by
means of arthrotomy, future improvement could be
achieved by shifting this open surgery procedure to
arthroscopy during the implantation of tissue-engineered
construct.
We have successfully performed an autologous
‘chondrocyte-fibrin’ construct (ACFC) implantation to
restore osteochondral defects in a sheep model (Munirah
et al., 2007). Although the 3D nature of ACFC has allowed
easier surgical handling and produced good results, at 12
weeks post-transplantation, the implantation was still
carried out by means of open surgery. Besides, since
ACFC was too soft to stay in the defect independently,
periosteum – which was reported to induce formation of
hypertrophic tissue (Peterson et al., 2000) – was used to
secure ACFC into the osteochondral defect. Another trial
on the restoration of osteochondral defects in patellar
groove of rabbits, utilising the press-fit method and fibrin
sealant, conducted by Uematsu et al. (2005), demonstrated
that in some implants, consisting of PLGA-seeded cells,
it had extruded from the defect. Therefore, in a search for
ways to apply minimally invasive surgery for cartilage
restoration, basic research is still necessary to develop its
full potential. We believe a better outcome will be obtained
by improving the scaffold materials of tissue-engineered
constructs rather than by using currently available
technique.
Hybridisation of various synthetically derived and
naturally derived biodegradable polymers has been widely
used for scaffold tissue engineering (Fan et al., 2006;
Khang et al., 2003; Kim et al., 2006; Kim et al., 2007;
Ko et al., 2007). Advantages of synthetically derived
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biodegradable polymers include controllable degradation
rate, high reproducibility and ease of fabrication into
specific shapes. Naturally derived biodegradable polymers
usually mimick key elements of normal tissue (Khang et
al., 2004; Park et al., 2005). Poly(lactic-co-glycolic acid)
(PLGA) is  bioabsorbable and biocompatible material,
making it a promising material in the context of
regenerative medicine. Numerous attempts have been
made for successful tissue reconstruction using PLGA-
based scaffold, either by PLGA itself (Park et al., 2005;
Uematsu et al., 2005) or by incorporation of PLGA with
natural polymers such as collagen (Chen et al., 2006a;
Chen et al., 2006b), extracellular matrix scaffolds – namely
small intestinal submucosa (Kim et al., 2006; Lee et al.,
2004) and demineralised bone particles (Jang et al., 2005).
In the present study we aimed to evaluate in vivo
formation of cartilaginous tissue in PLGA, utilizing a fibrin
carrier matrix, after implantation in nude mice. Our
preliminary results indicated that fibrin was an ideal cell
transplantation matrix and enhanced in vitro chondro-
genesis of rabbit articular chondrocytes (Munirah et al.,
2008a) and intervertebral disc cells (Munirah et al., 2008b)
in PLGA scaffolds. Fibrin, clinically applied as fibrin glue,
is a natural polymer that forms during blood coagulation.
Fibrin has been widely used for cartilage reconstruction
purposes (Munirah et al., 2007; Munirah et al., 2006).
Recently, Endres et al. (2007) showed that the 3D
arrangement of human articular chondrocytes in human
fibrin glue and resorbable polyglycolic acid (PGA)
scaffolds, cultured in the presence of human serum, is an
excellent system for the maturation of cartilage grafts in
articular cartilage regeneration. Several previous studies
also demonstrated that the fibrin immobilisation techniques
promoted homogeneous cell distribution and bone
formation, when using human periosteum-derived
progenitor cells in PLGA (Zheng et al., 2006), PLGA-
TCP composites (Arnold et al., 2002) and PLGA-
polydioxanon fleeces (Perka et al., 2000).
This report describes the formation of in vitro and in
vivo cartilaginous tissue in a fibrin/PLGA scaffold. The
results that demonstrated the feasibility of fibrin/PLGA as
an ideal cell transplantation matrix for chondrogenesis and
a structural basis for tissue-engineered articular cartilage
are presented.
Materials and Methods
Harvest of cartilage, chondrocytes isolation and
monolayer culture expansion
Articular cartilage was aseptically dissected from the
femoral condyles and patellae of 6 weeks-old New Zealand
White rabbits (n=6). Each sample was placed in normal
saline and processed within 6 to 12 hours post-surgery.
Cartilage was washed with phosphate buffered saline (PBS
1X, pH 7.2) (Gibco, Grand Island, NY, USA) containing
100 µg/ml penicillin and 100 µg/ml streptomycin (Gibco).
Sample was then minced into small fragments and digested
with 0.6% collagenase A (Roche Applied Science,
Mannheim, Germany) at 37°C for 6 hours, for chondrocyte
isolation. The resulting cell suspension was centrifuged at
1,500rpm, 5 min, 37oC (BHG, Hermle Z 360 K, Wehingen,
Germany). The supernatant was decanted and the cell pellet
was washed with PBS to remove the remaining enzyme.
After final centrifugation, the cell pellet was resuspended
in PBS, for total cell count with a haemocytometer (Hausser
Scientific, Horsham, PA, USA). Cell viability was
determined using the trypan blue dye exclusion test
(Gibco). Harvested chondrocytes were then seeded in 6
well-plates (Falcon, Franklin Lakes, NJ), with the initial
seeding of 5,000 cells/cm2 in the primary passage (P0).
Chondrocytes were cultured in the mixture of equal
volume of F12 nutrient mixture (F12) and Dulbecco’s
Modified Eagle Medium (DMEM) (Gibco), supplemented
with 10% foetal bovine serum (FBS) (Gibco) with the
presence of antibiotics and antimycotic (Gibco), 200 mM
L-glutamine (Gibco), 50 µg/ml of ascorbic acid (Sigma)
and 15 mM N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonic acid (HEPES) buffer 1M (Gibco) – as
previously described (Ruszymah et al., 2007a; Ruszymah
et al., 2007b). All cultures were maintained in a 5% CO2
incubator (Optima Model 560, Optima Inc, Tokyo, Japan)
at 37oC, with the medium changed every other day.
Preparation of microporous 3D PLGA scaffolds
PLGA copolymer (mole ratio 50:50, molecular weight
33,000 g/mole, Resomer RG 503 H) was purchased from
Boehringer Ingelheim Pharma GmbH (Ingelheim,
Germany). Micro-porous 3D PLGA scaffolds were
fabricated by solvent casting/salt leaching technique using
methylene chloride (CH2Cl2) (JT Baker, Baker Analyzed
®
A.C.S reagent, Selangor, Malaysia), as previously
described (Kim et al., 2006; Khang et al., 2003). In this
method, sieved sodium chloride (NaCl) particles
(approximately 180 µm) were dispersed in a polymer/
solvent solution (0.2% w/v concentration of PLGA in
methylene chloride), which was then cast to make a
cylindrical disk scaffold using silicone moulds (7 mm in
diameter and 3 mm in thickness). The salt particles were
leached out by continuous soaking in deionised water for
48 hours. This selective dissolution produces highly porous
polymer. The 3D PLGA scaffolds were freeze-dried for
24 hours in a freeze-dryer (IlShin Lab Co., Seoul, South
Korea), to remove any remaining solvent. The average of
pore diameter; 139.4 µm and porosity: 85.2% was
determined by the mercury intrusion porosimeter; an
AutoPore II 9220 (Micromeritics Co., Norcross, GA,
USA). PLGA scaffolds were sterilised with 70% ethanol
and washed three times with PBS before use.
Formation of in vitro constructs
Manufactured scaffolds were assigned into two
experimental groups – cultured chondrocytes were seeded
into (1) PLGA scaffolds with fibrin (fibrin/PLGA) and (2)
PLGA scaffolds without fibrin. Cultured chondrocytes
from the primary passage (P0) were trypsinised and sub-
cultured (P1) in 75 cm2 culture flasks (Falcon) at a density
of 5,000cells/cm2. After the cells reached confluency, the
P1 cells were harvested, counted for total cell and viability.
Approximately, one million cells per scaffold were
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incorporated and resuspended in the (1) commercially
available fibrin glue kit from Greenplast® (Green Cross P.
D. Company, Yongin, Korea) and (2) culture medium.
Greenplast fibrin glue kit consists of four vials – vial (1)
lyophilized fibrinogen, (2) aprotinin solution, (3)
lyophilized thrombin and (4) calcium chloride (CaCl2)
solution. Greenplast fibrinogen (65–115 mg/ml) was
diluted in culture medium and the thrombin concentration
(400–600 units/ml) was adjusted, using calcium chloride
solution, in vial 4 to obtain a final working solution
containing approximately 30-60 mg/ml fibrinogen and 10-
50 units/ml thrombin – as suggested by the manufacturer.
PLGA scaffolds were soaked carefully in the chondrocyte-
fibrin suspension and polymerized, by dropping thrombin-
CaCl2 solution on to the scaffolds. For control group, PLGA
scaffolds were soaked in chondrocytes suspended in culture
medium. All constructs were cultured for 3 weeks in vitro,
prior to implantation in vivo. Cell viability was assessed
by a modified 3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyltetrazolium-bromide (MTT, Sigma, St. Louis,
MO, USA) method that measured the reduction of a
tetrazolium component (MTT) into an insoluble formazan
product, by the mitochondria of viable cells. At a defined
day, all constructs were transferred into new plates with 1
ml of new medium. 100 µl of MTT solution (5 mg/ml stock
in PBS) was added into each well for 4 hrs incubation at
37°C. Next, all constructs were transferred into another
new plate and the crystals formed were dissolved by using
1 ml dimethylsulfoxide (DMSO, Sigma) per scaffold. 100
µl of solubilised mixture was transferred into 96-well
microtiter plates and then the absorption intensity was
analyzed using an ELISA plate reader at 590 nm (E-max,
Molecular Device, MDS Analytical Technologies,
Sunnyvale, CA, USA). Data were expressed as mean ±
standard error of mean (SEM) of 6 samples (n=6).
Implantation of the constructs
Athymic nude mice were anaesthetized upon surgery.
Minor skin incision was made at the dorsum of nude mice.
Four constructs were implanted into the unconnected
subcutaneous pockets of each nude mouse. Eighteen mice
were used in this experiment (total implants, 72: PLGA/
fibrin = 36, PLGA only = 36). The resulting in vivo
constructs were harvested at 1, 2 and 4 weeks post-
implantation. At time of explantation, all constructs were
dissected free from the nude mice, weighed and processed
for histological analysis, gene expression study and
sulphated glycosaminoglycan (sGAG) content.
Macroscopic observation, histological evaluation and
immunohistochemistry analysis
Each construct was observed grossly at room temperature,
without any fixation, and palpated with forceps clinically
to assess mechanical rigidity. Samples were then prepared
for histological analyses. After fixation with 10% formalin
for 24 hours, specimens were embedded in paraffin blocks
and sectioned with a Leica microtome. All sections were
then deparaffinised, rehydrated and stained with
Haematoxylin and Eosin (H&E) to assess tissue
morphology, Safranin O staining, to identify the presence
of proteoglycan-rich matrix, and Alcian blue staining, to
detect accumulation of GAG, were applied.
Immunohistochemistry analysis was performed in
accordance to the manufacturer’s protocol (UltraTek HRP
Kit, Immunotech, Marseille, France). All slides were
deparaffinised, rehydrated and pre-treated with 0.4%
pepsin (v/v 0.01N Hydrochloric acid) (Sigma-Aldrich, Inc.
USA) at room temperature for 30 minutes. Slides were
washed with PBS (Gibco). To reduce non-specific
background staining, due to endogenous peroxidase, slides
were incubated with hydrogen peroxide for 10 minutes.
All sections were then treated with peroxidase block (Super
Block, UltraTek HRP Kit; ScyTek Laboratories, Logan,
UT, USA) for 10 minutes prior to antibody incubation.
Monoclonal mouse anti-rabbit collagen type II
(Calbiochem® EMD Biosciences Inc., La Jolla) and
monoclonal mouse anti-rabbit collagen type I (Sigma
Aldrich) antibodies were diluted (1:1000) with antibody
DILUENT (DAKO Cytomation) and were applied to the
sections for 60 minutes. After washing with PBS, UltraTek
anti-polyvalent biotinylated antibody (UltraTek HRP Kit)
was applied to the slides for 10 minutes at room
temperature. Slides were then incubated with streptavidin-
peroxidase (UltraTek HRP Kit) for 10 minutes. After
washing with PBS, the signal was finally visualized as a
brownish precipitate, using freshly prepared chromogen
substrate 3-amino-9-ethylcarbazole (AEC) (UltraTek AEC
Kit). Sections were counterstained with Mayer’s
Haematoxylin and mounted, using permanent aqueous
mounting medium (SkyTek Laboratories).
Total RNA isolation, cDNA synthesis and
conventional PCR
Total RNA was extracted from in vitro and in vivo
constructs to build up a profile of changes in gene
expression. Approximately, 1.0x105 cells were
homogenised using 1ml TRIzol reagent (Invitrogen,
Carlsbad, CA). Cell lysate was centrifuged at 12,000 rpm,
at 4oC for 5 minutes (Mega 17R, Hanil Science Industrial
Co, Inchon, Korea). The supernatant was then transferred
into a 15 ml centrifugal tube (Falcon). Chloroform (Sigma-
Aldrich) was added into the tube containing the supernatant
and was then shaken vigorously for 10 seconds. After 10
minutes incubation at the room temperature, the mixture
was then separated into an aqueous phase, containing RNA,
an interphase and organic phase by centrifugation at 12,000
rpm for 15 minutes at 4oC. The aqueous phase containing
RNA was carefully transferred into a new 15 ml centrifugal
tube. Isopropanol (Sigma-Aldrich) was then mixed
homogeneously into the tube, to precipitate the total RNA.
5 µl of polyacryl carrier (Molecular Research Center,
Cincinnati) was added to the mixture to facilitate RNA
precipitation. The resulting total RNA was washed with
75% ethanol and air-dried. Yield and purity of the extracted
RNA was determined spectrophotometrically (BioRad,
Hercules, CA, USA).
Reverse transcription was carried out using
SuperscriptTM II Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA), according to the manufacturer’s
protocol. Total RNA (100-ng) was reverse transcribed in
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a 31µl reaction volume containing oligo(dT)12-18 (500
µg/ml), dNTP mix (10 mM), sterile distilled water, 5X
First-strand buffer (250 mM Tris-HCl, pH 8.3 at room
temperature, 375 mM KCl; 15 mM MgCl2), 0.1 M DTT,
RNaseOUTTM (40 units/µl and SuperscriptTM II RT under
the following conditions: 65 ºC for 5 minutes, 42 ºC for 2
minutes, 42 ºC and 70 ºC for 50 minutes and 15 minutes
respectively). Polymerase chain reaction protocol was
carried out in a 20 µl reaction volume containing 10 µl of
2x concentrated PCR master mix (Roche Applied Science,
Germany), 3 µl of reverse-transcribed reaction mixture,
10 µM primers and sterile PCR water (Roche Applied
Science) using the Takara Thermal Cycler (Takara Bio Inc.
Japan). After initial denaturation of the templates at 94oC,
polymerase chain reaction was performed for 25 cycles at
94oC for 30 seconds, at 52o C for 30 seconds, at 72oC for
30 seconds and final extension at 72oC for 5 minutes. The
PCR primers for detecting collagen type II, aggrecan core
protein and collagen type I were designed from previous
sequences as reported elsewhere (Ha et al. 2006; Yamazaki
et al. 2002). Primer sequences were as follows: collagen
type II: forward: 5’-gcacccatggacattggaggg-3’ / reverse:
5’-atgttttaaaaaatacgaag-3’ (Ha et al., 2006). Aggrecan core
protein: forward: 5’-atcaacagagacctacgatgt-3’ / reverse: 5’-
gttagggtagaggtagaccgt-3’ (Yamazaki et al., 2002).
Collagen type I: forward: 5’-gatgcgttccagttcgagta-3’ /
reverse: 5’-ggtcttccggtggtcttgta-3’ (Ha et al., 2006). The
gene for rabbit β-actin was used as an endogenous control.
The sequences for rabbit β-actin primer set (Yamazaki et
al., 2002) were: forward: 5’-ccggcttcgcgggcgacg-3’ /
reverse: 5’-tcccggccagccaggtcc-3’. All primers were
prepared by GenoTech. Corp. (Daejeon, Korea). 6 µl of
the amplified PCR products were separated by 1.5%
agarose gel electrophoresis (SeaKem® LE Agarose,
Cambrex Bio Science, Rockland, ME, USA), stained with
SYBR® Green Nucleic Acid Gel stain (Cambrex Bio
Science) and visualised by UV transillumination, using a
gel documentation system EDAS 290 Kodak (Viber
Lourmat,  Touray, France).
Sulphated glycosaminoglycan (sGAG) production
assay
All samples were lyophilised and treated with papain
digestion solution (125 µg/ml of papain, 5 mM L-cysteine,
100 mM Na2HPO4, 5 mM EDTA, pH 6.8) at 60°C for 16
hours. The sGAG contents were analyzed using a 1,9-
dimethylmethylene blue (DMMB) assay (Whitley et al.,
1989). Each sample was mixed with the DMMB solution
and the absorbance was measured at 590 nm wavelength.
Total sGAG of each sample was extrapolated using a
standard plot of shark chondroitin sulphate (Sigma Aldrich)
in the range of 0-50 µg/ml and normalized by the dry-
weight of each sample (n=6), as a relative sGAG content
(%). The dry-weight of each sample was determined after
lyophilisation. Data was expressed as mean ± standard
error of the mean (SEM) of 6 samples (n=6). Results were
analyzed using Student’s t-test and the difference are
considered significance when p<0.05.
Results
Cell proliferation and viability
After cell seeding, cells adhered to the scaffolds,
proliferated and produced cartilaginous matrices to fill void
spaces in the scaffold. The fibrin/PLGA hybrid construct
and PLGA (control) constructs exhibited similar cell
growth pattern, as determined by means of MTT assay
(Figure 1). From the chart, it can be seen that cell
proliferation increased gradually from day-1 until day-7.
The fibrin/PLGA hybrid construct showed a significantly
higher cell viability and proliferation activity, compared
to the PLGA at day-3. Next, by day-14, cell proliferation
in the fibrin/PLGA and PLGA had increased significantly
by 2.13x and 2.03x, respectively. Cell proliferation then
declined by day-21, in both groups. It has been indicated
that the early stage of chondrogenesis involves the activity
to establish cell-to-cell communication and cell-to-matrix
interaction, with regards to new cartilaginous tissue
Figure 1. Fibrin/PLGA and PLGA group exhibited similar cell growth pattern in vitro (n=6). The MTT assay
showed cell proliferation was gradually increased from day 1 until day 7, with fibrin/PLGA showing significantly
higher cells proliferation activity (p< 0.05) compared to PLGA at day 3. Next, cell proliferation activity in the
fibrin/PLGA and PLGA was significantly increased by day 14. The proliferation activity then declined by day 21 in
both groups.
45
S Munirah et al.                                                                          Fibrin/PLGA hybrid scaffold for cartilage formation in vivo
formation, which causes cellular proliferation to become
less active.  This may be a possible explanation to a
significant reduction of cell proliferation by 1.37x in the
fibrin/PLGA construct after 21 days.
Macroscopic observation of in vivo constructs
After being cultured for 3 weeks in vitro, fibrin/PLGA
hybrid and PLGA constructs were implanted
subcutaneously at the dorsum of athymic nude mice (Figure
2a). After 1, 2 and 4 weeks implantation, no evidence of
superficial infection or fistula formation was demonstrated
in the nude mice. All constructs were easily dissected from
the subcutaneous tissue (Figure 2b). After implantation,
both fibrin/PLGA and PLGA constructs maintained their
original rounded cylindrical shape, with a slight reduction
in the size when compared to in vitro specimens. However,
no significant variation was found between fibrin/PLGA
and PLGA. Figure 2c represented in vitro fibrin/PLGA
hybrid and PLGA constructs before implantation. All
fibrin/PLGA hybrid and PLGA constructs exhibited
smooth and glistening cartilage-like properties at each time
point of 1 week (Figure 2d), 2 weeks (Figure 2e) and 4
weeks (Figure 2f) after implantation. Gross examination
showed no evidence of malignant invasion in any of
specimens. A thin vascularised capsule was observed
surrounding the construct. Fibrin/PLGA hybrid and PLGA
constructs preserved their original rounded shapes
throughout the 4 week implantation.
Figure 2. Figure 2a represents the subcutaneously implanted construct at the dorsum part of athymic nude mice. No
evidence of superficial infection or fistula formation was demonstrated in the nude mice (Figure 2b). Figure 2c
represents in vitro fibrin/PLGA and PLGA constructs before implantation. At time of explantation, gross examination
showed no evidence of malignant invasion in any of the specimens. A thin vascularised capsule was observed
surrounding the constructs. All fibrin/PLGA and PLGA constructs exhibited smooth and glistening appearance at
each time point of 1 week (Figure 2d), 2 week (Figure 2e) and 4 weeks (Figure 2f).
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Figure 3. Before implantation (in vitro), a greater number of round morphological chondrocytes embedded in
basophilic ECM were observed in fibrin/PLGA than in PLGA. The pericellular and inter-territorial matrix was
strongly stained by Safranin O, to indicate presence of proteoglycan-rich matrix. The deposition of accumulated
GAG was further demonstrated by positive Alcian blue staining. After 1, 2 and 4 weeks implantation, the in vivo
fibrin/PLGA construct demonstrated superior cartilaginous histoarchitecture properties, when compared to PLGA,
in terms of cells distribution, cells-matrix organization and overall ECM production.
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Figure 4. Collagen type II exhibited strong immunopositivity in the in vitro fibrin/PLGA constructs, mainly localised
surrounding pericellular and inter-territorial matrix. After implantation, fibrin/PLGA showed more homogeneous
distribution of collagen type II than PLGA. Collagen type I in fibrin/PLGA showed moderate immunopositivity throughout
the ECM of specimens. Interestingly, after 4 weeks implantation, collagen type I showed either very weak or no expression
in both fibrin/PLGA and PLGA.
Figure 5. Gel photos are representative
of the mRNA expression analysis of
in vitro and in vivo fibrin/PLGA (n=6)
and PLGA constructs (n=6) using RT-
PCR.  The expression of genes
encoded cartilage-specific markers;
collagen type II and aggrecan core
protein was gradually expressed in all
constructs. Collagen type I was down-
regulated in fibrin/PLGA and PLGA
group after implantation.
 
β-actin gene
was steadily expressed in all samples;
to verify the analysis was reliable and
successful.
Notes:
M: 100bp marker
F/P: fibrin/PLGA
P: PLGA
IN VITRO:
1: week 1, 2: week 2, 3: week 3
IN VIVO:
1: week 1, 2: week 2, 4: week 4
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Histological evaluation of in vitro and in vivo
constructs
The morphology of cells and distribution of cartilaginous
ECM in the fibrin/PLGA hybrid and PLGA scaffolds were
examined by means of histological staining; namely H&E,
Safranin O staining and Alcian blue staining (Figure 3).
Before implantation, H&E staining showed that
chondrocyte clusters and ECM had filled void spaces of
fibrin/PLGA hybrid scaffold. In vitro fibrin/PLGA
constructs exhibited superior histo-architectural
characteristics of cartilage-like tissue, when compared to
the PLGA group. Closely-packed cartilage-isolated cells
were homogeneously distributed in the basophilic ground
substance. The pericellular and inter-territorial matrix was
strongly stained by the characteristic red of Safranin O, to
indicate presence of proteoglycan-rich matrix.
Cartilaginous ECM deposition was further demonstrated
by positive Alcian blue staining to confirm presence of
accumulated GAG. Next, formation of cartilaginous tissue
in fibrin/PLGA hybrid constructs was remarkably
evidenced at each time point of 1, 2 and 4 weeks after in
vivo implantation. The difference between fibrin/PLGA
hybrid construct and control group was clearly visible in
term of overall cartilaginous tissue formation, cells
organization and ECM distribution in the specimens.
Fibrin/PLGA constructs exhibited good quality cartilage-
like tissue, when compared to the control group.
Immunohistochemistry analysis
We analysed collagen type II and collagen type I
immunolocalization in the fibrin/PLGA hybrid construct,
and compared it with PLGA group at 1, 2 and 4 weeks
post-implantation (Figure 4). Collagen type II was detected
in all specimens. Collagen type II exhibited strong
immunopositivity at the specific region of in vitro fibrin/
PLGA hybrid construct, mainly localized at the pericellular
and inter-territorial matrix. After in vivo implantation,
fibrin/PLGA hybrid construct showed more homogenous
collagen type II distribution than in the PLGA scaffold, at
each time point. Analysis of collagen type I in fibrin/PLGA
hybrid constructs showed moderate immunopositivity
throughout ECM, at each time point of 1 and 2 weeks post-
implantation. Interestingly, after 4 weeks implantation,
75% of implanted constructs showed no collagen I
expression, whilst the rest showed very weak expression.
Cartilage-specific phenotypic expression analysis
When the mRNA expression of the fibrin/PLGA hybrid
construct and PLGA group were compared, both showed
comparable potential in sustaining the specific
chondrogenic phenotype. The expression of gene encoded
cartilage-specific markers, collagen type II and aggrecan
core protein, was steadily observed in in vitro culture –
whereas collagen type I, the cartilage dedifferentiation
marker, exhibited down-regulation pattern after 2 weeks
in vitro. After implantation, collagen type II and aggrecan
core protein mRNA expression was better than in vitro
specimens. Collagen type I was detected in all in vivo
specimens, but the expression was weaker than in the in
vitro samples. The house-keeping gene, β-actin was
steadily expressed in all specimens, to verify that the
analysis was reliable and successful. Results were
summarised in Figure 5.
Sulphated glycosaminoglycan (sGAG) production
assay
Normalised by dry-weight of each sample (n=6), the
relative sGAG content (%) was significantly higher
(p<0.05) in fibrin/PLGA hybrid constructs compared to
control at 1 week and 3 week in vitro culture. With
0.223±0.010 relative sGAG content, fibrin/PLGA hybrid
constructs exhibited 1.92x higher sGAG production than
the PLGA group; 0.116±0.025 at week 1. At week-2 there
was no significant difference between the two groups, with
the relative sGAG content in fibrin/PLGA hybrid
constructs being 0.197±0.037 and PLGA group 0.113
±0.042. By week 3, fibrin/PLGA hybrid constructs
exhibited 0.296± 0.011 relative sGAG content, which was
1.67x higher than the relative sGAG content in the PLGA
group; 0.177± 0.027. After implantation, the relative sGAG
Figure 6. sGAG production in fibrin/PLGA was better than in PLGA at each time point before and after implantation
(n=6). The relative sGAG contents (%) were significantly higher (p<0.05) in fibrin/PLGA compared to PLGA at
week 1 and week 3 in vitro and after 2-week implantation (*).
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content (%) in fibrin/PLGA hybrid construct was given
by 0.349 ± 0.043 (1 week), 0.696 ± 0.042 (2 weeks) and
0.723 ± 0.045 (4 weeks). The relative sGAG content in
fibrin/PLGA hybrid group increased significantly by 2
weeks post-implantation by 1.99x. While, in PLGA
construct, the relative sGAG content (%) was 0.286 ± 0.021
(1 week), 0.562 ± 0.042 (2 weeks) and 0.650 ± 0.038 (4
weeks). Results were summarised in Figure 6.
Discussion
Tissue-engineered cartilage constructs should meet certain
criteria in order to improve surgical handling and to
withstand mechanical loading. Since synthetically derived
biodegradable polymers can be moulded easily into the
desired shapes with proper mechanical strength, they have
been used as a skeleton for a mechanically weak natural
polymer to withstand tissue collapse. The hybrid polymers
used in this study are a Food and Drugs Administration
(FDA) approved copolymer, lactic acid and glycolic acid,
and the commercially available natural polymer fibrin from
Greenplast®. Fibrin was reported to be an ideal cell carrier
(Eyrich et al., 2007), to provide homogenous cells
distribution without significant cell loss, during cell seeding
procedures (Zheng et al., 2006). In this study, we evaluated
the formation of in vivo cartilaginous tissue using rabbit
articular chondrocytes seeded in fibrin/PLGA hybrid
scaffold at each time point of 1, 2, and 4 weeks post-
implantation.
Our in vitro results indicated that chondrocytes-seeded
in fibrin/PLGA secreted cartilage-specific ECM molecules
and developed chondrocyte-chondrocyte interaction, to
form clusters of various sizes, while preserving the original
shapes of cells. Immobilization of cells in fibrin resulted
in homogenous cell distribution in PLGA scaffolds.
Moreover, the deposition of newly developed cartilaginous
ECM in fibrin/PLGA was histologically superior to that
of PLGA group. This phenomenon may be due to higher
cell seeding efficiency and homogeneity in fibrin/PLGA
than in PLGA. Homogenous distribution of cells was also
observed during the osteogenesis of human periosteum-
derived progenitor cells in fibrin/PLGA (Zheng et al.,
2006), while Lee et al. (2005) reported superior uniformity
of chondrocytes, distributed in fibrin-filled polyurethane
scaffold, when compared to polyurethane scaffold without
fibrin.
After implantation, both fibrin/PLGA and PLGA
constructs maintained their original rounded cylindrical
shape, with a slight reduction in the size when compared
to in vitro specimens. However, no significant variation
was found between fibrin/PLGA and PLGA. All constructs
showed cartilage-like properties with a white, smooth and
glistening appearance, as reported elsewhere (Munirah et
al., 2005, 2007). Fibrin/PLGA showed histologically
mature chondrocytes and extensive development of
cartilaginous ECM, indicated by presence of an abundant
proteoglycan-rich matrix and accumulated GAG.
Conversely, the PLGA group exhibited minimal cartilage
histoarchitecture in vitro – indicated by few rounded cells
in the void spaces of the scaffold. The entire PLGA scaffold
was covered with newly developed cartilaginous ECM
after only 4 weeks implantation. The incorporation of fibrin
into the scaffold visibly facilitated formation of high quality
cartilaginous tissue (Endres et al., 2007). Conversely, Jin
et al. (2007) reported that in vitro differentiated human
adipose-derived stem cells, seeded in PLGA, rapidly lost
their chondrocytic phenotype and failed to produce
cartilaginous tissue in vivo. Only fibrous tissues and
angiogenesis invasions were observed after 4 weeks
implantation.
Although there were remarkable histological
differences between fibrin/PLGA and PLGA groups, there
were no significant variations in the semi-quantitative gene
expression for collagen type II, aggrecan core protein or
collagen type I. Cartilage-specific chondrocyte phenotype
was maintained in both groups. However, the expression
of collagen type II and aggrecan core protein, improved
after in vivo implantation, suggesting a mature cartilaginous
phenotype. Interestingly, collagen type I expression
demonstrated a down-regulation pattern after 2 and 3
weeks in vitro. However, the expression remained visible
after 4 weeks implantation. On the contrary,
immunohistochemistry against collagen type I denoted that
75% of implanted constructs showed no collagen I
expression after 4 weeks implantation. This contradictory
observation may have been due to the discrepancy between
mRNA level and protein level analysis. Sasano et al. (1999;
2001) reported chondrocytes that rat tibial articular
cartilage synthesised collagen type I and accumulated
protein in ECM, during articular cartilage development.
Absence of appropriate mechanical stimuli in the
subcutaneous dorsum is believed to elicit some
unfavourable effects on the maturation of neo-cartilage
(Chen et al., 2004). Accordingly, the arrangement of
articular chondrocytes in fibrin and PLGA scaffolds is an
excellent system for maturation of cartilaginous tissues.
Significant elevation of sGAG after implantation suggested
progress towards development of cartilaginous tissue in
fibrin/PLGA. If this result is applicable for future clinical
use, a better outcome would be obtained than by using the
currently available treatment methods.
Conclusions
Fibrin/PLGA scaffold promotes cellular proliferation and
cartilaginous tissue formation of rabbit articular
chondrocytes. This study suggests that fibrin/PLGA hybrid
scaffold may serve as a potential cell delivery vehicle and
a structural basis for tissue-engineered articular cartilage.
Future study utilising autologous in vivo system in big
animal model is necessary to validate the feasibility of
fibrin/PLGA hybrid scaffold and cells composite for
articular cartilage restoration.
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Discussion with Reviewers
S. Grad: The pore size of 90-180µm appears to be
relatively small. A proper cell seeding procedure is
therefore crucial to achieve a uniform cell distribution. It
is unclear how the cells were seeded, since the descriptions
in the abstract and methods section vary. Were different
seeding methods evaluated? Also, a common observation
in chondrocyte-seeded scaffolds is the development of a
prominent layer rich in extracellular matrix at the edges of
the constructs. Was this phenomenon also noticed in PLGA
and/or fibrin/PLGA constructs?
Authors: The reviewer is correct. Initially, we seeded the
cells directly onto scaffold but, as the reviewer mentioned
above, a common observation in chondrocyte-seeded
scaffolds is the development of a prominent layer rich in
extracellular matrix at the edges of the constructs.
Therefore, we tried to soak the scaffold carefully in cells-
fibrin admixture and cell suspension in culture medium.
To achieve a uniform cell distribution, we introduced some
mechanical force, using a pipette, to aid cellular infiltration
throughout the scaffold.
S. Grad: How do the amounts of sGAG/dry weight
compare to values of native articular cartilage?
Authors: The aim of this study was not to regenerate a
complete native cartilage tissue, that would be ideal for
replacing articular cartilage loss, but more towards
developing a cell delivery system for effective cartilaginous
tissue formation from chondrocytes, as well as to
demonstrate the applicability of fibrin-cells-PLGA
complex. This is the reason why we only compared fibrin/
PLGA and PLGA.
D. Eglin:  At the concentration of fibrinogen used, the
viscosity of the solution is very high and by dropping the
thrombin-CaCl2 on the top of the scaffold, without mixing,
it is likely that the homogeneity of the gel in the PLGA
scaffolds may not be optimal and the gel formation (e.g.,
cross-link density) may also be heterogeneous. (more
cross-linking on the surface than in the bulk of the PLGA
scaffolds. Did the authors check the fibrin gel homogeneity
in the PLGA scaffolds?
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Authors: 65–115 mg/ml and 400–600 units/ml is a
working concentration of fibrinogen and thrombin
recommended by the manufacturer for general procedure
during surgery. However, since we were using cells,
fibrinogen and the thrombin-CaCl2 solution concentrations
had to be modified. The fibrinogen concentration was
diluted to approximately 30-60 mg/ml, with culture
medium, and the thrombin solution was diluted to 10-50
units/ml, with CaCl2 solution, to achieve at least 15 to 30
sec clotting time – as suggested by the manufacturer. This
has been included in the text. We did not check the fibrin
gel homogeneity in PLGA, as such, but we did notice a
homogenous formazan crystal distribution in the fibrin/
PLGA construct as well as the PLGA construct, during
the MTT assay. We believe this phenomenon was very
much associated with cells-fibrin homogeneity in PLGA.
Furthermore, histological evaluation of in vitro constructs
demonstrated a homogenous cells distribution in fibrin/
PLGA scaffold.
